Skip to main content

The Viral “Tripledemic” Opportunity

Between Covid, the flu, and RSV, investors in over-the-counter consumer pharmaceutical companies might be wondering if now is a logical time to up their holdings in the companies that make cold and flu medicines. Let’s take a look.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.